Heron Therapeutics | HRTX - Passivo Circulante





Passivo Circulante Alterar Data
ALKERMES USD 599.5M 56.06M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amarin USD 179.64M 14.82M 2026-03
ANI Pharmaceuticals USD 239.51M 38.6M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
Eisai JPY 340.25B 47.42B 2026-03
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Esperion Therapeutics USD 300.36M 451K 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Insmed USD 361.01M 107.87M 2026-03
Ligand Pharmaceuticals USD 40.67M 3.22M 2026-03
Merck USD 26.94B 1.38B 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Omeros USD 85.5M 2.28M 2025-06
Pacira USD 108.79M 11.8M 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Surmodics USD 19.44M 1.1M 2025-06
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Veracyte USD 56.11M 3.82M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03